Italy, Switzerland, Austria freeze sales of Novartis flu vaccines

October 24, 2012

Italian, Swiss and Austrian authorities on Wednesday halted the sale of flu vaccines made by Swiss pharmaceutical giant Novartis.

The Italian said it has banned the sale and use of several flu vaccines produced by Novartis pending tests into possible side-effects.

"The health ministry and the Italian medicines agency (AIFA) have decided to take the precaution of banning immediately the use of the vaccines" Aggripal, Fluad and Influpozzi, it said.

On the basis of information supplied by Novartis, AIFA "has decided that it is necessary to carry out further tests regarding the quality and the safety" of the vaccines, which "can produce collateral effects," the statement said.

In Switzerland, the national drug agency Swissmedic said it was ordering the "immediate halt of deliveries from Novartis," due to "possible ".

The alarm was raised after white particles were seen in syringes carrying the vaccines, Swissmedic said, stressing that they could be nothing more than little of the vaccine's components.

The Swiss decision affects some 160,000 , Swissmedic said, adding that it was unclear whether the problem affected vaccines already available in Switzerland.

The freeze on sales of the vaccines and their use was "a simple precaution" and those who had already been vaccinated for the flu "had nothing to worry about", it added.

In Austria, a spokeswoman for Novartis's Austrian subsidiary said that "further deliveries of the Novartis flu vaccines were stopped today (Wednesday)."

She added that the move was a precautionary measure following the moves by Italy and Switzerland.

stu-ide-nl/har

In their statement explaining the freeze on vaccine imports, Italian authorities said they had "decided that it is necessary to carry out further tests regarding the quality and the safety" of the vaccines.

burs/har

In Austria, a spokeswoman for Novartis's Austrian subsidiary said that "further deliveries of the Novartis flu vaccines were stopped today (Wednesday)."

She added that the move was a precautionary measure following similar decisions by Italy and Switzerland.

Explore further: New development could increase flu vaccine supply

Related Stories

New development could increase flu vaccine supply

June 2, 2011
(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound ...

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.